Fig. 2

Forest plots of the pCR rates in single-arm studies (only one treatment group) (a): combination of pertuzumab with HER2 inhibitors for patients with HER2+ breast cancer; forest plots of the pCR rates in controlled studies (two treatment groups) (b): combination of pertuzumab with HER2 inhibitors versus HER2-targeted therapies without pertuzumab for patients with HER2+ breast cancer. CI = confidence interval; HER2 = human epidermal growth factor receptor 2, HR+ = hormone receptor positive, HR- = hormone receptor negative, pCR = pathologically complete response